| GYRE THERAPEUTICS |
| USA |
| Gesundheit |
| US4037831033 / A3EE5F |
| L9S (Frankfurt) / GYRE (NASDAQ) |
| FRA:L9S, ETR:L9S, L9S:GR, NASDAQ:GYRE |
| - |
| https://www.gyretx.com/ |
|
Gyre Therapeutics Inc. is a biotechnology firm dedicated to the discovery and development of innovative therapies for unmet medical needs. Its primary function is to leverage cutting-edge research and..
>Volltext.. |
| 638.83 Mio. EUR |
| 618.85 Mio. EUR |
| 92.39 Mio. EUR |
| 12.34 Mio. EUR |
| 5.73 Mio. EUR |
| 0.06 EUR |
| 1 Mio. EUR |
| 34.8 Mio. EUR |
| 1.74 Mio. EUR |
| 3.77 |
| -46.81% |
| - |
| - |
| - |
| - |
| - |
| GYRE THERAPEUTICS, GYRE THERAPEUTIC |
| 12.03.26 |
|